Health Economics›Ovarian cancer›First-line chemotherapy for advanced stage disease

First-line chemotherapy for advanced stage disease

Ovarian cancer · 20 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 32 363	28d	14.1 mo	43.4 mo	7	R 224 167 PFS proxy	9
Carboplatin and Pegylated liposomal doxorubicin Variant #03	—	R 13 338	28d	19.0 mo	—	7	R 93 364 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Nintedanib Variant #01	—	R 9 950	21d	17.2 mo	—	2	R 19 900 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	~4.7 mo	~22.3 mo	~6	~R 33 004 PFS proxy · indirect	4
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	20.0 mo	—	2	R 8 829 PFS proxy	—
CEP Variant #01	—	R 2 211	28d	—	—	~6	~R 13 269 indirect	—
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	16.4 mo	36.8 mo	7	R 9 204 PFS proxy	2
CISCA Variant #02	—	R 1 258	21d	—	—	~6	~R 7 550 indirect	—
Carboplatin and Cyclophosphamide Variant #01	—	R 1 221	28d	—	—	~6	~R 7 323 indirect	—
Chlorambucil and Cisplatin Variant #01	—	R 1 030	21d	—	—	~12	~R 12 361 indirect	—
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	17.2 mo	40.6 mo	12	R 12 296 PFS proxy	21
Cisplatin and Cyclophosphamide Variant #01	—	R 839	21d	—	—	~6	~R 5 034 indirect	—
Hexa-CAF Variant #01 Partial	—	R 773	28d	—	—	~2	~R 1 546 indirect	—
Cisplatin, Cyclophosphamide, Interferon gamma-1b Variant #01 Partial	—	R 739	28d	—	—	~6	~R 4 432 indirect	—
CHAD Variant #01 Partial	—	R 726	28d	—	—	~2	~R 1 453 indirect	—
Cisplatin monotherapy Variant #01	—	R 588	21d	—	~19.5 mo	~2	~R 1 177 PFS proxy · indirect	1
Carboplatin monotherapy Variant #01	—	R 535	21d	12.1 mo	33.0 mo	2	R 1 070 PFS proxy	2
Altretamine and Cisplatin (HD) Variant #01 Partial	—	R 294	21d	—	—	~2	~R 588 indirect	—
Melphalan monotherapy Variant #01	—	R 73	42d	~50.0 mo	~22.2 mo	~18	~R 1 320 PFS proxy · indirect	7
CAP (Platinol) Partial	—	—	—	—	—	—	—	—

20 of 20 regimens shown